Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Targets and Bioactive Molecules - Seite 2

Under the terms of the agreement, Bristol-Myers Squibb will be granted exclusive rights to intellectual property and therapies generated during the collaboration. Enterome will receive an upfront payment of $15 million for access to its technology plus R&D funding. Enterome is also eligible to receive preclinical and clinical milestone payments for each licensed therapeutic candidate plus royalties on net sales. Enterome is eligible for additional milestone payments in relation to new diagnostic products discovered and developed during the collaboration.

Further details of the agreement were not disclosed.

About the Microbiome and Immuno-Oncology 

In the past decade, an explosion of research in the microbiome field has revealed a remarkable symbiotic relationship between the gut bacteria and its human host, enhancing biotech companies' interest in manipulating this relationship to improve human health. Scientists have shown that the gut microbiome plays an important role in regulating metabolism, influencing the chemistry in the brain, acting as a barrier to pathogens and regulating the immune system. In the cancer context, recent publications have demonstrated the role of the intestinal microbiome in mediating immune activation in response to chemotherapeutic agents. New cancer immunotherapies have improved outcomes in cancer patients and their combination with microbiome-based therapeutics may help to boost the immune system and potentially lead to improved outcomes in more patients.

About Bristol-Myers Squibb 

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, and YouTube.

About Enterome 

Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.

Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.